Abstract
The Vesicular Acetylcholine Transporter (VAChT) is found throughout the cholinergic nervous system and is responsible for transporting Acetylcholine (ACh) into synaptic vesicles for storage. Deterioration of cholinergic neurotransmission is a known pathophysiological hallmark of Alzheimers disease (AD). Ligands that bind to VAChT – particularly in the brain and CNS where cholinergic neurotransmission is vital for memory and cognitive function – may facilitate the study of cholinergic pathway regulation in the CNS and serve as useful diagnostic agents for AD. Vesamicol was the first VAChT ligand identified, however its poor selectivity has prompted the search for more potent and selective compounds. Numerous structural modifications to the vesamicol scaffold have been explored and several classes of VAChT ligands are highlighted in this review. The affinity and selectivity of these ligands for VAChT and -receptors are discussed.
Keywords: Alzheimer's disease, benzovesamicol, CNS, structure-activity relationship, VAChT, vesamicol
Current Bioactive Compounds
Title: Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease
Volume: 6 Issue: 3
Author(s): Nicolas Giboureau, Kylee M. Aumann, Corinne Beinat and Michael Kassiou
Affiliation:
Keywords: Alzheimer's disease, benzovesamicol, CNS, structure-activity relationship, VAChT, vesamicol
Abstract: The Vesicular Acetylcholine Transporter (VAChT) is found throughout the cholinergic nervous system and is responsible for transporting Acetylcholine (ACh) into synaptic vesicles for storage. Deterioration of cholinergic neurotransmission is a known pathophysiological hallmark of Alzheimers disease (AD). Ligands that bind to VAChT – particularly in the brain and CNS where cholinergic neurotransmission is vital for memory and cognitive function – may facilitate the study of cholinergic pathway regulation in the CNS and serve as useful diagnostic agents for AD. Vesamicol was the first VAChT ligand identified, however its poor selectivity has prompted the search for more potent and selective compounds. Numerous structural modifications to the vesamicol scaffold have been explored and several classes of VAChT ligands are highlighted in this review. The affinity and selectivity of these ligands for VAChT and -receptors are discussed.
Export Options
About this article
Cite this article as:
Giboureau Nicolas, M. Aumann Kylee, Beinat Corinne and Kassiou Michael, Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease, Current Bioactive Compounds 2010; 6 (3) . https://dx.doi.org/10.2174/157340710793237353
DOI https://dx.doi.org/10.2174/157340710793237353 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
cAMP Signalling in the Kinetoplastid Protozoa
Current Molecular Medicine Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery The Role of Wnt/Beta-Catenin Signaling in Renal Carcinogenesis: Lessons from Cadmium Toxicity Studies
Current Molecular Medicine A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study
Current Vascular Pharmacology Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Drug Induced QT Prolongation: Lessons from Congenital and Acquired Long QT Syndromes
Current Drug Targets - Cardiovascular & Hematological Disorders Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry Nutrient and Qualitative Phytochemical Analysis-evaluation of Antimicrobial Activity and Development of Products with Mulberry Leaves (<i>Mulberry indica</i> L.)
Current Nutrition & Food Science Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design The p35 Family of Apoptosis Inhibitors
Current Genomics Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets